Ruchika Goel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ruchika Goel has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Debashish Danda
Department of Clinical Immunology and Rheumatology Christian Medical College Vellore India
11 shared publications - John Mathew
Christian Medical College
6 shared publications - George Joseph
Department of Cardiology, Christian Medical College, Vellore, India
3 shared publications P Sandhya
3 shared publications- Aswin Nair
Department of Clinical Immunology and Rheumatology, Christian Medical College Vellore, Vellore, India
2 shared publications - Hindhumathi Mohan
Department of Clinical Immunology and Rheumatology, Christian Medical College, Tamil Nadu, Vellore, India
2 shared publications
Latest Publications
- 27 January 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (7) , 2805-2819
Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort
Background Consensus on treatment of idiopathic inflammatory myositis (IIM), particularly with regard to flares and interstitial lung disease (ILD), does not exist. We studied the long-term outcome and treatment response in our large, retrospective cohort of adult South-Asian patients exclusively with IIM. Methodology Electronic records of IIM patients satisfying inclusion and exclusion criteria were studied longitudinally at presentation, at 3, 6, 12, 18 and 24 months and thereafter yearly till their last follow up (F/u) visit. Depending on clinical, imaging, and muscle enzyme profile during the F/u period, patients were categorised as complete (CR) and partial responders (PRs). Parameters favouring CR were assessed using multivariate logistic regression analysis. Outcome parameters and flares on immunosuppressants (IS) were then assessed in patients with/without ILD. Results Two hundred thirty-two patients with median F/u duration of 44.5 months (25–80.25) were included. ILD was seen in 40.1%. Patients with non-Jo1 anti-synthetase antibodies (n=26) were numerically more than those with Jo-1 antibody (n=24). CR status was attained by 50.9% patients. Absence of pericardial effusion (p=0.042, OR 4.223, 95% CI: 1.05–16.9) and presence of Gottron’s rash (p=0.044, OR 1.78, 95% CI 1.017–3.121) at baseline predicted CR by multivariate regression. Majority received mycophenolate during the entire F/u period. Discontinuation of steroids was feasible in 51.7% after a median duration of 24 months (18–42). After excluding patients with ILD, flares were numerically lesser in patients only on mycophenolate compared with those only on methotrexate (p=0.06). Further flares were curtailed when switched from other agents to mycophenolate. Conclusion Mycophenolate is an effective treatment option in IIM patients with and without co-existing ILD. Presence of Gottron’s rash and absence of pericardial effusion were found to be predictors of favourable clinical outcome in this largest single-centre study. Key points • This largest single-centre study of South Asian adult patients with idiopathic inflammatory myositis showed good clinical outcome and survival with combination treatment regimen consisting of upfront immunosuppressant especially mycophenolate mofetil or sodium (MMF/MMS) along with tapering doses of steroids. • Absence of pericardial involvement and presence of Gottron’s rash were predictors of complete responders in our overall patient cohort. • Testing anti-Jo-1 antibody alone during evaluation of myositis will overlook important prognostic biomarkers such as the presence of non-Jo 1 antisynthetase autoantibodies (PL-7, PL-12, EJ and OJ) as well as Ro52; our cohort had more patients with non-Jo 1 antibodies than Jo-1 antibody; hence, there is a strong case for testing the entire spectrum of myositis autoantibodies in IIM. • Patients on MMF/MMS therapy from onset or even those switched to mycophenolate later had a better outcome, irrespective of their interstitial lung disease status.
- 27 January 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (7) , 2805-2819
Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort
Background Consensus on treatment of idiopathic inflammatory myositis (IIM), particularly with regard to flares and interstitial lung disease (ILD), does not exist. We studied the long-term outcome and treatment response in our large, retrospective cohort of adult South-Asian patients exclusively with IIM. Methodology Electronic records of IIM patients satisfying inclusion and exclusion criteria were studied longitudinally at presentation, at 3, 6, 12, 18 and 24 months and thereafter yearly till their last follow up (F/u) visit. Depending on clinical, imaging, and muscle enzyme profile during the F/u period, patients were categorised as complete (CR) and partial responders (PRs). Parameters favouring CR were assessed using multivariate logistic regression analysis. Outcome parameters and flares on immunosuppressants (IS) were then assessed in patients with/without ILD. Results Two hundred thirty-two patients with median F/u duration of 44.5 months (25–80.25) were included. ILD was seen in 40.1%. Patients with non-Jo1 anti-synthetase antibodies (n=26) were numerically more than those with Jo-1 antibody (n=24). CR status was attained by 50.9% patients. Absence of pericardial effusion (p=0.042, OR 4.223, 95% CI: 1.05–16.9) and presence of Gottron’s rash (p=0.044, OR 1.78, 95% CI 1.017–3.121) at baseline predicted CR by multivariate regression. Majority received mycophenolate during the entire F/u period. Discontinuation of steroids was feasible in 51.7% after a median duration of 24 months (18–42). After excluding patients with ILD, flares were numerically lesser in patients only on mycophenolate compared with those only on methotrexate (p=0.06). Further flares were curtailed when switched from other agents to mycophenolate. Conclusion Mycophenolate is an effective treatment option in IIM patients with and without co-existing ILD. Presence of Gottron’s rash and absence of pericardial effusion were found to be predictors of favourable clinical outcome in this largest single-centre study. Key points • This largest single-centre study of South Asian adult patients with idiopathic inflammatory myositis showed good clinical outcome and survival with combination treatment regimen consisting of upfront immunosuppressant especially mycophenolate mofetil or sodium (MMF/MMS) along with tapering doses of steroids. • Absence of pericardial involvement and presence of Gottron’s rash were predictors of complete responders in our overall patient cohort. • Testing anti-Jo-1 antibody alone during evaluation of myositis will overlook important prognostic biomarkers such as the presence of non-Jo 1 antisynthetase autoantibodies (PL-7, PL-12, EJ and OJ) as well as Ro52; our cohort had more patients with non-Jo 1 antibodies than Jo-1 antibody; hence, there is a strong case for testing the entire spectrum of myositis autoantibodies in IIM. • Patients on MMF/MMS therapy from onset or even those switched to mycophenolate later had a better outcome, irrespective of their interstitial lung disease status.
- 1 December 2017
- Published by Springer Nature in Rheumatology International
- Vol. 38 (4) , 623-630
Study of serial serum myeloid-related protein 8/14 as a sensitive biomarker in Takayasu arteritis: a single centre study
The aim of the study was to explore utility of serial serum myeloid-related protein 8/14 (MRP8/14) as a biomarker of clinical disease activity and angiographic progression in Takayasu arteritis (TA). Serum MRP8/14 levels were assayed by commercial ELISA for 85 TA patients and 24 healthy controls at baseline, and for 56 and 21 TA patients during follow-up visits R1 and R2, respectively. Disease was categorised as active, indeterminate and stable according to Indian Takayasu Arteritis score (ITAS 2010), ITAS-A(CRP) and angiography. Patients were divided into responders and non-responders/relapsers based on treatment response. Non-parametric tests were used for inter-group comparisons at baseline and during follow-up time points. Generalised Estimating Equation was used to study association between changes in serial MRP8/14 levels and disease activity. At baseline, median MRP8/14 levels were higher in patients with TA than healthy controls [7353 (4524 to11283) vs 4896 (3194 to 8474.5) ng/ml, p = 0.011]. Patients with active disease had higher levels [8552 (5463–12488)] than stable disease [5292.5 (3140.5–7310)], p = 0.002, and healthy controls [4896 (3194–8474.5)], p = 0.001. Changes in serial MRP8/14 level were associated with changes in disease activity, independent of steroid dose, p = 0.000. At R1, MRP 8/14 levels were lower than baseline in responders (n = 38) [9146.0 (6296.8–13693.8) vs 6501 (4314.8–8304.5), p = 0.004], but did not change in non-responders/relapsers (n = 14) [6693.5(4210.8–10516.3) vs 7755.0(5342–10741.0), p = 0.42]. Similar trend was observed at R2. MRP8/14 levels increased during follow-up in 66% and 26.3% of angiographic progressors and non-progressors, respectively. MRP8/14 in TA may act as a novel biomarker with prognostic implications.
- 1 December 2017
- Published by Springer Nature in Rheumatology International
- Vol. 38 (4) , 623-630
Study of serial serum myeloid-related protein 8/14 as a sensitive biomarker in Takayasu arteritis: a single centre study
The aim of the study was to explore utility of serial serum myeloid-related protein 8/14 (MRP8/14) as a biomarker of clinical disease activity and angiographic progression in Takayasu arteritis (TA). Serum MRP8/14 levels were assayed by commercial ELISA for 85 TA patients and 24 healthy controls at baseline, and for 56 and 21 TA patients during follow-up visits R1 and R2, respectively. Disease was categorised as active, indeterminate and stable according to Indian Takayasu Arteritis score (ITAS 2010), ITAS-A(CRP) and angiography. Patients were divided into responders and non-responders/relapsers based on treatment response. Non-parametric tests were used for inter-group comparisons at baseline and during follow-up time points. Generalised Estimating Equation was used to study association between changes in serial MRP8/14 levels and disease activity. At baseline, median MRP8/14 levels were higher in patients with TA than healthy controls [7353 (4524 to11283) vs 4896 (3194 to 8474.5) ng/ml, p = 0.011]. Patients with active disease had higher levels [8552 (5463–12488)] than stable disease [5292.5 (3140.5–7310)], p = 0.002, and healthy controls [4896 (3194–8474.5)], p = 0.001. Changes in serial MRP8/14 level were associated with changes in disease activity, independent of steroid dose, p = 0.000. At R1, MRP 8/14 levels were lower than baseline in responders (n = 38) [9146.0 (6296.8–13693.8) vs 6501 (4314.8–8304.5), p = 0.004], but did not change in non-responders/relapsers (n = 14) [6693.5(4210.8–10516.3) vs 7755.0(5342–10741.0), p = 0.42]. Similar trend was observed at R2. MRP8/14 levels increased during follow-up in 66% and 26.3% of angiographic progressors and non-progressors, respectively. MRP8/14 in TA may act as a novel biomarker with prognostic implications.
- 1 July 2017
- Published by Elsevier in Human Immunology
- Vol. 78 (7-8) , 515-520
Interleukin-17F and interleukin-6 gene polymorphisms in Asian Indian patients with Takayasu arteritis
- 1 July 2017
- Published by Elsevier in Human Immunology
- Vol. 78 (7-8) , 515-520
Interleukin-17F and interleukin-6 gene polymorphisms in Asian Indian patients with Takayasu arteritis
- Open Access
- 1 November 2014
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 9, S14
PET CT imaging is an insensitive tool for disease activity assessment in patients with Takayasu's arteritis on treatment
- 1 November 2014
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 9, S14
Open AccessPET CT imaging is an insensitive tool for disease activity assessment in patients with Takayasu's arteritis on treatment
- Open Access
- 30 November 2011
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 6 (3) , S9-S10
P20 Clinical profile of anti-Ku autoantibody: a cohort study from a tertiary care centre in south India
- 30 November 2011
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 6 (3) , S9-S10
Open AccessP20 Clinical profile of anti-Ku autoantibody: a cohort study from a tertiary care centre in south India
- Open Access
- 30 November 2011
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 6 (3) , S3
O10 Serum alanine amino transferase—a disease activity marker in inflammatory myositis?
- 30 November 2011
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 6 (3) , S3
Open AccessO10 Serum alanine amino transferase—a disease activity marker in inflammatory myositis?
- Open Access
- 30 November 2010
- Published by Medknow in Indian Journal of Rheumatology
- Vol. 5 (3) , S15
P7 Pancreatitis in systemic lupus erythematosus—case series over a period of three years from a tertiary care centre in South India
- 30 November 2010
- Published by Medknow in Indian Journal of Rheumatology
- Vol. 5 (3) , S15
Open AccessP7 Pancreatitis in systemic lupus erythematosus—case series over a period of three years from a tertiary care centre in South India
- Open Access
- 30 November 2010
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 5 (3) , S24
P46 TNF-α polymorphism in Takayasu's Arteritis—a preliminary study from tertiary centre in South India
- 30 November 2010
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 5 (3) , S24
Open AccessP46 TNF-α polymorphism in Takayasu's Arteritis—a preliminary study from tertiary centre in South India
- Open Access
- 30 November 2010
- Published by Medknow in Indian Journal of Rheumatology
- Vol. 5 (3) , S8
O21 Profile of serum pro-inflammatory versus anti-inflammatory cytokine and their correlation with disease activity in takayasu arteritis
- 30 November 2010
- Published by Medknow in Indian Journal of Rheumatology
- Vol. 5 (3) , S8
Open AccessO21 Profile of serum pro-inflammatory versus anti-inflammatory cytokine and their correlation with disease activity in takayasu arteritis
- 7 January 2010
- Published by Springer Nature in Clinical Rheumatology
- Vol. 29 (3) , 329-332
Mycophenolate mofetil in Takayasu’s arteritis
Mycophenolate mofetil (MMf) has recently been reported as a useful alternative immunosuppressive drug in autoimmune diseases. There is paucity of literature on its use in Takayasu's arteritis (TA). The aim of this study was to assess the safety and efficacy of MMf in Asian Indian patients with Takayasu's arteritis. Records of 21 consecutive patients with TA on treatment with oral MMF attending our centre from January 2005 to August 2008 were studied. The clinical, laboratory and angiography findings were noted and disease activity assessment was done using Indian Takayasu's arteritis activity score (ITAS) and physician's global observation score at baseline and last follow-up. Eleven patients were on steroids alone at baseline while ten patients had received azathioprine prior to administration of mycophenolate. The mean duration of follow-up on mycophenolate was 9.6 (±6.4) months. Nineteen patients (90%) received mycophenolate due to active disease, while in the other two patients, it was given to facilitate steroid tapering. Mycophenolate had to be discontinued in one patient due to skin rash. At the last visit, all the remaining 20 patients who continued mycophenolate had improvement in disease activity as evident by the drop in median ITAS [7 (range 0–19) versus 1 (range 0–7); p = 0.001]. A similar trend was noted in laboratory markers of inflammation with a reduction in mean Erythrocyte Sedimentation Rate (ESR) (68 ± 36.5 versus 43.2 ± 34 mm/first hour; p = 0.003) and mean C - Reactive protein (CRP) (31 ± 46.7 versus 17.3 ± 23.9 mg/L; p = 1.00). All patients received concomitant steroids, but there was a significant decrease in steroid dosage from 36 (±16) mg/day at baseline to 19 (±14) mg/day at last follow-up (p < 0.001). This study is the largest series till date establishing the use of mycophenolate as a safe and effective steroid-sparing immunosuppressant in Takayasu's arteritis.
- 7 January 2010
- Published by Springer Nature in Clinical Rheumatology
- Vol. 29 (3) , 329-332
Mycophenolate mofetil in Takayasu’s arteritis
Mycophenolate mofetil (MMf) has recently been reported as a useful alternative immunosuppressive drug in autoimmune diseases. There is paucity of literature on its use in Takayasu's arteritis (TA). The aim of this study was to assess the safety and efficacy of MMf in Asian Indian patients with Takayasu's arteritis. Records of 21 consecutive patients with TA on treatment with oral MMF attending our centre from January 2005 to August 2008 were studied. The clinical, laboratory and angiography findings were noted and disease activity assessment was done using Indian Takayasu's arteritis activity score (ITAS) and physician's global observation score at baseline and last follow-up. Eleven patients were on steroids alone at baseline while ten patients had received azathioprine prior to administration of mycophenolate. The mean duration of follow-up on mycophenolate was 9.6 (±6.4) months. Nineteen patients (90%) received mycophenolate due to active disease, while in the other two patients, it was given to facilitate steroid tapering. Mycophenolate had to be discontinued in one patient due to skin rash. At the last visit, all the remaining 20 patients who continued mycophenolate had improvement in disease activity as evident by the drop in median ITAS [7 (range 0–19) versus 1 (range 0–7); p = 0.001]. A similar trend was noted in laboratory markers of inflammation with a reduction in mean Erythrocyte Sedimentation Rate (ESR) (68 ± 36.5 versus 43.2 ± 34 mm/first hour; p = 0.003) and mean C - Reactive protein (CRP) (31 ± 46.7 versus 17.3 ± 23.9 mg/L; p = 1.00). All patients received concomitant steroids, but there was a significant decrease in steroid dosage from 36 (±16) mg/day at baseline to 19 (±14) mg/day at last follow-up (p < 0.001). This study is the largest series till date establishing the use of mycophenolate as a safe and effective steroid-sparing immunosuppressant in Takayasu's arteritis.